News Consolidation in psychedelics as atai pairs with Beckley Beckley Psytech has agreed to merge with atai Life Sciences in a deal that would bring together two psychedelic medicine pioneers.
News Beckley's psychedelic med inches forward in depression UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.
News One of J&J's blockbuster depression hopes has flamed out Johnson & Johnson has halted the development of aticaprant as a treatment for major depressive disorder, blowing a hole in its late-stage pipeline.
News Supernus reports less than super data for depression drug Supernus Pharma has suffered a blow to its R&D pipeline after a candidate for treatment-resistant depression failed a phase 2b trial.
News GH Research leaps on psychedelic data in depression After setbacks with psychedelics, phase 2b data with GH Research's GH001 for treatment-resistant depression could lift confidence in the category.
News J&J's Spravato gets another lift with new FDA approval Johnson & Johnson's Spravato has become the first standalone drug to be cleared by the FDA for adults with treatment-resistant depression.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
